HLA-DR Antibody (1083110) [CoraFluor™ 1]

Name: HLA-DR Antibody (1083110) [CoraFluor™ 1]
Brand: Novus Biologicals
SKU: FAB11555CL1
Price: 959 USD
Availability: InStock

Novus Biologicals | Catalog # FAB11555CL1

Submit a review

Product Documents

View Available Conjugates

100% Guarantee

Product Specifications
Scientific Data
Applications
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Species Reactivity

Human

Applications

Immunohistochemistry, Western Blot

Label

CoraFluor 1

Antibody Source

Monoclonal Mouse IgG_2B Clone # 1083110

View all HLA-DR Primary Antibodies »

Product Specifications

Immunogen

Synthetic Peptide
Accession # P01903

Specificity

Detects a synthetic peptide around aa 100 in Direct ELISA.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG_2B

Description

CoraFluor(TM) 1 is a high performance terbium-based TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) or TRF (Time-Resolved Fluorescence) donor for high throughput assay development. CoraFluor(TM) 1 absorbs UV light at approximately 340 nm, and emits at approximately 490 nm, 545 nm, 585 nm and 620 nm. It is compatible with common acceptor dyes that absorb at the emission wavelengths of CoraFluor(TM) 1. CoraFluor(TM) 1 can be used for the development of robust and scalable TR-FRET binding assays such as target engagement, ternary complex, protein-protein interaction and protein quantification assays.

CoraFluor(TM) 1, amine reactive

CoraFluor(TM) 1, thiol reactive

For more information, please see our CoraFluor(TM) TR-FRET technology flyer.

Scientific Data Images for HLA-DR Antibody (1083110) [CoraFluor™ 1]

Product Feature: CoraFluor Probes for TR-FRET

CoraFluor™ 1, amine reactive (Catalog:7920) and CoraFluor™ 2, amine reactive (Catalog # 7950) are terbium-based probes that have been developed for use as TR-FRET donors. They emit wavelengths compatible with commonly used fluorescent acceptor dyes such as BODIPY® (or BDY) and Janelia Fluor® dyes, FITC (Catalog # 5440), TMR and Cyanine 5 (Catalog # 5436). CoraFluor™ fluorescence is brighter and more stable in biological media than existing TR-FRET donors, leading to enhanced sensitivity and improved data generation. CoraFluor™ 1 exhibits excitation upon exposure to a 337 nm UV laser.

Applications for HLA-DR Antibody (1083110) [CoraFluor™ 1]

Application

Recommended Usage

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.

Application Notes

Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Formulation

PBS

Preservative

No Preservative

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark. Do not freeze.

Background: HLA-DR

Human Leukocyte Antigen -DR isotype (HLA-DR) is a major histocompatibility complex (MHC) class II molecule expressed by antigen presenting cells (APCs) that plays a significant role in immune response (1). Class II molecules also include isoforms HLA-DP and -DQ (1,2). These type I membrane glycoproteins on APCs present peptides to helper T cells and T cell receptors on CD4+ cells (1). In humans, the genes encoding class II MHC proteins are located on chromosome 6p21, where HLA-DR is typically the most highly expressed, followed by HLA-DQ and then HLA-DP (3). Structurally, HLA-DR molecules are heterodimers consisting of an alpha chain subunit with an approximate theoretical molecular weight of 34 kDa and one of many approximately 30 kDa beta subunits (1-3). The alpha and beta genes are considered highly polymorphic with duplication resulting in nine DRB (beta subunit of HLA-DR) genes (DRB1-DRB9); though only DRB1, DRB3, DRB4, and DRB5 are considered functional (2,3). On the other hand, the alpha subunit is encoded by a single DRA gene (2,3). Studies focusing on the structural and biochemical properties of peptides that bind to HLA-DR molecules have helped contribute to subunit vaccine design and development (3).

Given the role in adaptive immunity, HLA-DR allele polymorphisms, gene misexpression, and dysfunction has been implicated in many diseases ranging from autoimmune disorders to cancer (2). HLA-DR is also a classical biomarker for disease, including sepsis where reduced expression of HLA-DR molecules on monocytes, as measured by flow cytometry, indicates diagnosis and prognosis (4,5). Immunosuppression observed with sepsis results in decreased surface expression of HLA-DR and concurrent increase in expression of programmed death 1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), and B and T lymphocyte attenuator (BTLA) (4). This altered expression results in poor T cell response and apoptosis, along with reduced interferon-gamma (IFN-gamma) production and increased pro-inflammatory cytokine release (4). Furthermore, the decrease in HLA-DR expression is also correlated with the decrease in CD14lowCD16+ inflammatory monocytes (5). Interestingly, COVID-19 patients also exhibit a reduction in HLA-DR that correlates with disease severity and immunosuppression (5).

References

1. Andersson G. (1998). Evolution of the human HLA-DR region. Frontiers in bioscience : a journal and virtual library. https://doi.org/10.2741/a317

2. Shiina, T., Hosomichi, K., Inoko, H., & Kulski, J. K. (2009). The HLA genomic loci map: expression, interaction, diversity and disease. Journal of human genetics. https://doi.org/10.1038/jhg.2008.5

3. Stern, L. J., & Calvo-Calle, J. M. (2009). HLA-DR: molecular insights and vaccine design. Current pharmaceutical design. https://doi.org/10.2174/138161209789105171

4. Zhuang, Y., Peng, H., Chen, Y., Zhou, S., & Chen, Y. (2017). Dynamic monitoring of monocyte HLA-DR expression for the diagnosis, prognosis, and prediction of sepsis. Frontiers in bioscience (Landmark edition). https://doi.org/10.2741/4547

5. Benlyamani, I., Venet, F., Coudereau, R., Gossez, M., & Monneret, G. (2020). Monocyte HLA-DR Measurement by Flow Cytometry in COVID-19 Patients: An Interim Review. Cytometry. Part A : the journal of the International Society for Analytical Cytology. https://doi.org/10.1002/cyto.a.24249

Long Name

Major Histocompatibility Complex Class II DR

Alternate Names

HLA-DRA, HLADR, MHC Class II DR

Additional HLA-DR Products

Product Documents for HLA-DR Antibody (1083110) [CoraFluor™ 1]

Download Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for HLA-DR Antibody (1083110) [CoraFluor™ 1]

CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.